Speciality: Oncology
Description:
A warm welcome to all the medical professionals joining us in this interesting and informative session on the role of pazopanib in managing advanced renal cell carcinoma (RCC).
Kidney cancer, also known as renal cancer, is one of the more common cancers diagnosed in both men and women worldwide, and the incidence of this disease continues to rise steadily over time. Advanced RCC, classified as stage 4 kidney cancer, represents a particularly challenging condition to treat and is often associated with a poor prognosis due to its aggressive nature and tendency to spread to other organs.
In clinical practice, healthcare professionals primarily focus on slowing down the progression of advanced RCC, alleviating symptoms, and improving the overall quality of life for affected patients. Although complete cure is often difficult to achieve at this stage, ongoing research and clinical trials have led to the development of new treatment options that have received approval from the Food and Drug Administration (FDA), providing hope and improved outcomes for many patients.
One such promising treatment is pazopanib, an oral anti-cancer medication that works by blocking tumor cell growth through multiple mechanisms. It primarily targets a group of proteins called tyrosine kinases, which are found on the surface of cancer cells. These proteins play a critical role in signaling pathways that promote tumor growth and survival. Additionally, many of these targeted proteins are involved in angiogenesis, the process by which tumors develop new blood vessels to sustain their growth and spread.
By inhibiting these pathways, pazopanib can effectively reduce tumor vascularization and inhibit cancer progression. This makes it an important option in the management of advanced RCC, helping to extend patient survival and improve quality of life.
We encourage you to listen closely to this webinar, absorb the valuable insights being shared, and follow HiDoc for more such engaging and educational sessions that keep healthcare professionals updated with the latest advancements in oncology and other medical fields.
See More Webinars @ Hidoc Webinars
1.
Doctors say lung cancer is still the deadliest cancer, but hope is growing
2.
Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.
3.
FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.
4.
The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.
5.
Virtual Reality Travel Reduces Cancer Pain.
1.
Clinical Decision-Making in Oligometastatic Cancer: A Case-Based Perspective
2.
Iron Homeostasis Throughout the Female Lifespan
3.
The Benefits and Side Effects of Vidaza Syndrome
4.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
5.
Exercise Rehabilitation in Hematologic Disease Survivorship
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
3.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation